Skip to main content
MLEC logo

Moolec Science S.A. (MLEC) Stock Price & Analysis

Moolec Science S.A. (MLEC) — MoonshotScore 24/100 (Weak band), calculated Oct 5, 2026. Price $4.75 (-1.25%), as of the Oct 2, 2026 trading session; market cap $3.45M.

Educational signal · not a buy or sell recommendation · How to read this

$4.75 −$0.06 (-1.25%) Market Cap $3.45M

Moolec Science S.A. · MLEC

Moolec Science S.A. focuses on producing animal proteins in plants through Molecular Farming, operating in the alternative protein landscape. The company leverages the agronomic efficiency of target crops like soybeans and peas across the United States, Europe, and South America.

Price as of Oct 2, 2026

Key Statistics

24 of 100

MoonshotScore v2 · Moolec Science (MLEC)

Weak
Business Quality Average (40)
Financial Safety Strained (29)
Valuation Bubble (11)
Growth Durability Flat (49)
Momentum Falling (18)
Why this rating? Method, drivers & history

Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.

  • Business Quality — Is this a genuinely good business?
  • Financial Safety — Could this blow up on me?
  • Valuation — Am I paying a fair price?
  • Growth Durability — Is the growth real and likely to last?
  • Momentum — Is the market already moving on this?
The ten-second read ·

A strained balance sheet and an expensive valuation, though quality and growth are only middling, and the price trend has turned against it. Business Quality: Average; Financial Safety: Strained; Valuation: Bubble; Growth Durability: Flat; Momentum: Falling.

Earnings yield is the main valuation drag relative to sector peers.

  • quarterly revenue $3M (Q2 FY2024, quarter ended Dec 2024)
  • EPS beat 3 of 6
  • Altman Z -1.32 · Piotroski F 1

Holding back: balance-sheet strain, a rich price, weak price trend

What has the MoonshotScore done over time?

MoonshotScore snapshots recorded for MLEC (29 recorded, newest six shown)
RecordedScoreBand
24Weak
24Weak
24Weak
24Weak
24Weak
24Weak

The score was 24 in the stored Oct 4, 2026 snapshot and remains 24 in the current publication computed Oct 5, 2026 (0); the largest pillar moves were Growth Durability +1; the pillar moves offset under the sector-relative weighting, so the headline score is unchanged. This current publication is not yet represented in the immutable snapshot archive.

Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.

Computed · Educational signal · not a buy or sell recommendation · How the MoonshotScore is computed →

Price & valuation

As of
MeasureValue
Latest provided price$4.75
Change on the day-1.25%
52-week range$3.08 – $23.22
Market capitalisation$3.45M
Shares traded on the day44.9K

Price & events

Other perspectives

Council score for Moolec Science (MLEC): perspectives

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

9-Factor Breakdown

Revenue Growth Strong
Gross Margin Moderate
Operating Leverage Moderate
Cash Runway Neutral
R&D Intensity Weak
Insider Activity Moderate
Trading Liquidity Weak
Price Momentum Negative
News Sentiment Neutral

Legends Council

6 lenses, 0 current

AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built

Dalio-style lens (simulated) Ray Dalio Favorable read
Griffin-style lens (simulated) Ken Griffin Unfavorable read
Simons-style lens (simulated) Jim Simons Favorable read
Englander-style lens (simulated) Izzy Englander Neutral read
Klarman-style lens (simulated) Seth Klarman Neutral read
Moon AI lens (model) Neutral read

Read on: Sep 10, 2026 · older than the 27 hours refresh window; not a current reading

Munger's Mindset

Balance Sheet & Valuation · historical

Financial Health Neutral
Margin of Safety Fairly Valued
Profit Margin Weak
Revenue Growth Strong
Gross Margin Negative

Read on: Sep 10, 2026 · older than the 27 hours refresh window; not a current reading

How to read these bars and different assessments

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.

On Sep 10, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.

Readings on this page are from Oct 5, 2026, except a card that shows its own read date.

Watch the MLEC film — every key number, told as a short cinematic story

~2 min · open the film

1 · What is it?

What is Moolec Science (MLEC), and what does it report?

Short answer · as of

A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. Moolec Science S.A. (MLEC) is the company analyzed here. It employs 103 people and is led by Alejandro Antalich. In Q2 FY2024 it reported revenue of $3M and net income of -$2M. The market values it at $3.45M.

2 · Latest results

What do the latest results show for Moolec Science (MLEC)?

Short answer · as of

The most recent reported quarter, Q2 FY2024, carried revenue of $3M. Against analyst estimates the company has EPS beat 3 of 6 reports.

Quarterly income statement — 4 quarters
Revenue, net income and earnings per share by quarter
PeriodRevenueNet incomeEPS
Q2 FY2024$3M-$2M-$0.93 (diluted)
Q1 FY2024$2M-$2M-$0.74 (diluted)
Q4 FY2023$2M-$3M-$1.05 (diluted)
Q3 FY2023$2M-$1M-$0.56 (diluted)
3 · Financial strengths and risks

What are the financial strengths and risks for Moolec Science (MLEC)?

Short answer

What is holding it back is balance-sheet strain, a rich price, weak price trend. The distress and quality screens read Altman Z -1.32 · Piotroski F 1. Trailing ratios: ROE 376.8% · ROA -54.4% · current ratio 0.13.

Data-derived red flags

  • Financial-distress signal — its Altman Z-Score of -1.32 sits in the distress zone (elevated bankruptcy risk).
  • Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
4 · What to check next?

What should you watch next at Moolec Science (MLEC)?

Short answer · as of

Analyst estimates on file carry FY2027 revenue $77.33M · EPS 6.00 · 1 analysts.

What the records here don't tell us

  • The next earnings date is not yet scheduled in the calendar we read.
  • No insider Form 4 transaction falls inside the window this page reads.
  • The newest quarter held here (Q2 FY2024) was filed Apr 16, 2025 — 17 months ago.

Checked against the records this page reads, on the dates shown above.

5 · Peer comparison

How does Moolec Science compare with its peers?

Short answer

Moolec Science's score ranks 13th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.

Peer set — price, market value and MoonshotScore
CompanyPriceMarket valueScore
CorMedix Inc. (CRMD) Same industry, near in market value$7.19 Oct 2, 2026$564M94 5-pillar Oct 5, 2026
Rigel Pharmaceuticals, Inc. (RIGL) Same industry, near in market value$47.15 Oct 2, 2026$872M93 5-pillar Oct 5, 2026
Zevra Therapeutics, Inc. (ZVRA) Same industry, near in market value$9.99 Oct 2, 2026$591M91 5-pillar Oct 5, 2026
MiMedx Group, Inc. (MDXG) Same industry, near in market value$4.59 Oct 2, 2026$669M88 5-pillar Oct 5, 2026
Rallybio Corporation (RLYB) Same industry, near in market value$17.08 Oct 2, 2026$90.6M83 5-pillar Oct 5, 2026
ImmuCell Corporation (ICCC) Same industry, near in market value$9.75 Oct 2, 2026$88.2M77 5-pillar Oct 5, 2026
Pharming Group N.V. (PHAR) Same industry, near in market value$9.75 Oct 2, 2026$690M77 5-pillar Oct 5, 2026
Oramed Pharmaceuticals Inc. (ORMP) Same industry, near in market value$4.49 Oct 2, 2026$184M76 5-pillar Oct 5, 2026
Protalix BioTherapeutics, Inc. (PLX) Same industry, near in market value$2.71 Oct 2, 2026$218M73 5-pillar Oct 5, 2026
Niagen Bioscience Inc (NAGE) Same industry, near in market value$2.79 Oct 2, 2026$222M68 5-pillar Oct 5, 2026
Climb Bio, Inc. (CLYM) Same industry, near in market value$10.94 Oct 2, 2026$626M68 5-pillar Oct 5, 2026
AN2 Therapeutics, Inc. (ANTX) Same industry, near in market value$5.71 Oct 2, 2026$206M67 5-pillar Oct 5, 2026
Moolec Science (MLEC) — this page$4.75$3.45M24

Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.

The records behind this page

Analyst targets & estimates

What analysts have on file

Revenue estimate
$77.33M
EPS estimate
$6.00

Measured against a quoted price of $4.75 (as of Oct 2, 2026).

Moolec Science Stock: Key Questions Answered

These answers are editorial: 1 of these 9 answers is drawn from the MLEC research dossier (written Mar 17, 2026 by gemini-2.0-flash); the other 8 are question templates that restate figures shown above. Figures in this section are not part of the source register.

What does the MoonshotScore mean for MLEC?

MLEC carries the MoonshotScore stated above — the Weak band. This is an educational research signal, not a buy or sell recommendation. The number comes from the five-pillar engine (business quality, financial safety, valuation, growth durability, momentum), re-ranked daily against sector peers. Moolec Science S.A. focuses on producing animal proteins in plants through Molecular Farming, operating in the alternative protein landscape.

Is MLEC a good stock to buy?

Stock Expert AI does not rate MLEC buy, sell or hold. Moolec Science S.A. carries a MoonshotScore, in the Weak band, a research rating against its peers rather than a forecast. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.

What is the MLEC stock price today?

The last price recorded on this page for Moolec Science S.A. (MLEC) is $4.75, as of the Oct 2, 2026 trading session (source: Financial Modeling Prep (FMP) · quote). It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.

What are the main risks for MLEC?

Moolec Science S.A. faces several key risks, including competition from established players in the alternative protein market, regulatory hurdles in different countries, and the need for significant capital investment to scale production. The company's reliance on a limited number of crops, such as soybeans and peas, also poses a risk.

What are the key factors to evaluate for MLEC?

Moolec Science S.A. (MLEC) holds a MoonshotScore in the low range. Strategic Partnerships: Forming strategic partnerships with food manufacturers, ingredient suppliers, and agricultural companies can accelerate Moolec's growth and market penetration. Not financial advice.

How frequently does MLEC data refresh on this page?

MLEC's price is the last quote we recorded, from the Oct 2, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.

What has driven MLEC's recent stock price performance?

Moolec Science S.A. (MLEC) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Innovative Molecular Farming technology. See the News tab for the latest drivers. Past performance does not predict future results.

Should investors consider MLEC overvalued or undervalued right now?

Moolec Science S.A. (MLEC) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.

How do I research MLEC before investing?

Before investing in Moolec Science S.A. (MLEC), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 17, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.

Sources — records for every figure on this page (20 figures)

The 20 rows below are exactly the facts the evidence-backed sections of this page printed — the 10-second verdict, the MoonshotScore, price and market value, the five questions with their receipts, and the records behind this page. Known dates and sources are recorded on their own rows; an em dash or UNRECORDED tier preserves a stored observation without inventing either. The quarterly income statement is provider-standardized (FMP) under one row, and scale definitions — a 0-100 rating, the band ladder, the Piotroski 0–9 range — are fixed rather than measured. No number in those sections was generated by a model. The register does not cover quoted third-party headlines, the dated council readings, or the Frequently Asked Questions; each of those says where it came from where it stands.

"As of" is the date the value is true for where the source carries one — a quarter end, a filing date, a price close, the day the score was computed. A cached observation with no source date remains undated; the page publication date is not used as a substitute.

FMP — 8 facts from Financial Modeling Prep endpoint families

FMP facts used on this page
Fact IDFactValue as shownAs ofTierSource
px.lastLatest provided price$4.75FMPFinancial Modeling Prep (FMP) · quote — Dated to the US trading session the price belongs to, derived from the quote record's timestamp (weekend and pre-open reads roll back to the previous weekday; exchange holidays are not modelled). The record does not establish an exchange execution time. Retrieved 2026-10-05T00:54:37.325Z.
px.changeChange on the day-1.25%FMPFinancial Modeling Prep (FMP) · quote
px.mcapMarket capitalisation$3.45MFMPFinancial Modeling Prep (FMP) · quote — Date unknown Market cap record date: 2026-10-02. FMP quote timestamp: 2026-10-02T20:00:00.000Z. Captured from FMP at 2026-10-05T00:54:36.358Z. No share-count basis is inferred; this page preserves the reported amount instead of recalculating it from shares.
px.change_absChange on the day, in dollars−$0.06FMPFinancial Modeling Prep (FMP) · quote
fin.q_revenueRevenue, Q2 FY2024$3MFMPFinancial Modeling Prep (FMP) · income statement (quarterly)
px.volumeShares traded on the day44.9KFMPFinancial Modeling Prep (FMP) · quote
fin.q_incomeNet income, Q2 FY2024-$2MFMPFinancial Modeling Prep (FMP) · income statement (quarterly)
fin.q_tableQuarterly income statement4 quarters through Q2 FY2024FMPFinancial Modeling Prep (FMP) · income statement (quarterly), as filed

UNRECORDED — 9 facts from stored observations whose source was not recorded

UNRECORDED facts used on this page
Fact IDFactValue as shownAs ofTierSource
earn.historyReported versus estimated, recent quartersEPS beat 3 of 6UNRECORDEDStored earnings-history observation — Captured 2026-09-16 · Expired observation
fin.scoresDistress and quality screensAltman Z -1.32 · Piotroski F 1UNRECORDEDStored financial-scores observation — Captured 2026-10-05
px.range5252-week range$3.08 – $23.22UNRECORDEDStored company-profile observation — Captured 2026-10-02
id.employeesEmployees103UNRECORDEDStored company-profile observation — Captured 2026-10-02
id.ceoChief executiveAlejandro AntalichUNRECORDEDStored company-profile observation — Captured 2026-10-02
fin.ratiosReturn and yield ratios (trailing twelve months)ROE 376.8% · ROA -54.4% · current ratio 0.13—UNRECORDEDStored key metrics — Date unknown
earn.estimatesAnalyst estimates, next fiscal yearFY2027 revenue $77.33M · EPS 6.00 · 1 analystsUNRECORDEDStored analyst estimates — Captured 2026-06-16 · Expired observation
earn.est_revenueRevenue estimate, FY2027$77.33MUNRECORDEDStored analyst estimates — Captured 2026-06-16 · Expired observation
earn.est_epsEPS estimate, FY2027$6.00UNRECORDEDStored analyst estimates — Captured 2026-06-16 · Expired observation

OURS — 3 facts from Stock Expert AI's own score and rank

OURS facts used on this page
Fact IDFactValue as shownAs ofTierSource
ours.moonshotMoonshotScore v224 of 100 · Weak · pillars 40 / 29 / 11 / 49 / 18OURSStock Expert AI MoonshotScore v2 engine
ours.valuation_driverRecorded valuation score driverEarnings yield is the main valuation drag relative to sector peers.OURSStock Expert AI MoonshotScore v2 engine · stored factor contributions
ours.moonshot_changeMoonshotScore movement24 (stored snapshot Oct 4, 2026) → 24 (current publication computed Oct 5, 2026) (0)OURSStock Expert AI current score publication and immutable score snapshots — The current score publication is not yet represented in the immutable snapshot archive.
Published
Research standards
Methodology · Editorial policy · Corrections
Data Sources & Methodology
Figures come from Financial Modeling Prep (FMP). If FMP has no figure for a ticker, a price or fundamental may come from a Yahoo Finance fallback, or a price from an Alpaca fallback. SEC EDGAR is used only for filing links and company identity details (legal name, address), never for figures. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.
Data provided as-is for educational purposes. Not financial advice. Methodology

Data provided for informational purposes only.